Concepedia

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest,

The Lancet · 2015 · 831 citations · 29 references

DOI

Concepts

References

29

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +14

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

, , +15

Psoriasis causes as much disability as other major medical diseases

Stephen R. Rapp, Steven R. Feldman, M. Lyn Exum et al. · Journal of the American Academy of Dermatology · 1999 · 1.5K citations

, , +12

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

, , +15

Etanercept as Monotherapy in Patients with Psoriasis

Craig L. Leonardi, JEROLD L. POWERS, Robert Matheson et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

, , +16